LUNG
Pulmonx Corporation Healthcare Medical Devices
7/12
Innovation Score
Patent Activity
3/3
18 patents found
OK_NORMALIZED
Cash Runway
1/3
22 months of cash remaining based on current burn rate.
Cash on hand: $55.8M
Cash on hand: $55.8M
Revenue Trajectory
0/3
Revenue: $87.4M
YoY Growth: -4.6%
YoY Growth: -4.6%
Management Quality
3/3
Insider ownership: 11.0%
SBC/Revenue: 20.1%
No reverse splits detected
SBC/Revenue: 20.1%
No reverse splits detected
Key Metrics
Market Cap
$86.2M
Revenue
$87.4M
Revenue Growth (YoY)
-4.6%
Cash on Hand
$55.8M
Cash Runway
22 months
Shares Outstanding
42.2M
Insider Ownership
11.0%
SBC / Revenue
20.1%
Sector / Industry
Healthcare / Medical Devices
Patents (18)
Match type: OK_NORMALIZED
- Devices and systems for lung treatment
- Methods and systems for endobronchial diagnostics
- Methods, systems, and devices for analyzing lung imaging data
- Systems and methods for flushing an assessment catheter
- Measuring lung function and lung disease progression at a lobar/segmental level
7-Step Risk Assessment
How LUNG maps to our micro cap methodology:
- Innovation Signal 18 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 22 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory -4.6% YoY growth on $87.4M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 11.0% of shares. SBC is 20.1% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $86.2M company.
Financial Detail
Free Cash Flow
$-11.7M
FCF Yield
-13.6%
Return on Equity
-88.9%
Debt / Equity
143.4%
Gross Margin
77.1%
Profit Margin
-55.0%
Operating Margin
-39.8%
Price / Book
2.21
Current Ratio
4.32
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-08-08